PSG10P

Across TCGA pan-cancer cohorts, PSG10P Mutation is linked to patient survival in 8 of 34 cancer types, making it a survival-associated PSG10P data layer compared with 19 for mass-spec protein.

The strongest signal is observed in head and neck squamous cell carcinoma (HNSC), where higher PSG10P Mutation is associated with worse disease-free survival. In most high-consensus cancer types, elevated PSG10P expression acts as an unfavorable survival marker, although some lineages such as SKCM show a favorable association.

HNSC, BRCA, and ESCA are the cancer types where PSG10P Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
HNSC	DFS	Median	II,III,IV	0.127	0.612	.004	30	view →
BRCA	OS	Median	III,IV	0.001	0.907	<.001	24	view →
ESCA	OS	Median	III,IV	0.117	0.574	.001	24	view →
LUAD	DFS	Median	IV	0.047	0.565	<.001	17	view →
LGG	OS	Median	All	0.350	0.811	.018	6	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
LIHC	DFS	Median	All	0.149	0.555	.024	3	view →
SKCM	OS	Median	All	0.971	0.865	.049	1	view →

Pink = unfavorable, green = favorable. Showing the 8 strongest of 8 lineages.

PSG10P–HNSC (DFS)

Open the HNSC breakdown →